Isoxazoles: synthesis, evaluation and bioinformatic design as acetylcholinesterase inhibitors. 2013

Margarita Gutiérrez, and María Francisca Matus, and Tomas Poblete, and Jessica Amigo, and Gabriel Vallejos, and Luis Astudillo
Laboratorio Síntesis Orgánica, Instituto de Química de Recursos Naturales, Universidad de Talca, Talca.

OBJECTIVE Inhibition of acetylcholinesterase (AChE) is a common treatment for early stages of Alzheimer's disease. In this study, nine isoxazoles derivatives were tested for their in-vitro AChE activity. The molecular docking showed the interaction of the compounds with the active site. METHODS The isoxazoles were synthesized using 1,3-dipolar cycloaddition in the presence of sodium hypochlorite. They were also isolated and characterized by spectroscopic methods. The in-vitro activity was measured by an adapted version of Ellman's assay. RESULTS The isoxazoles are described as inhibitors of AChE. The most potent compound in the series exhibited a moderate inhibitory activity (50% inhibitory concentration = 134.87 μm). The design of new compounds was created by using the RACHEL module of the SYBYL software. CONCLUSIONS Our research provided enough evidence of the efficacy of isoxazoles as AChE inhibitors. The isoxazoles were synthesized and evaluated as inhibitors of AChE. The docking study based on a novel series of complexes isoxazole with AChE from Electroporus electricus has demonstrated that the ligand bind is similar to the compounds used as reference. To find new candidates with the isoxazole core that act as inhibitors of AChE, part of the structure of the compound 9 was used for de-novo design. Molecular docking models of the ligand-AChE complexes suggest that the compound 10 is located on the periphery of the AChE active site.

UI MeSH Term Description Entries
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking
D019295 Computational Biology A field of biology concerned with the development of techniques for the collection and manipulation of biological data, and the use of such data to make biological discoveries or predictions. This field encompasses all computational methods and theories for solving biological problems including manipulation of models and datasets. Bioinformatics,Molecular Biology, Computational,Bio-Informatics,Biology, Computational,Computational Molecular Biology,Bio Informatics,Bio-Informatic,Bioinformatic,Biologies, Computational Molecular,Biology, Computational Molecular,Computational Molecular Biologies,Molecular Biologies, Computational

Related Publications

Margarita Gutiérrez, and María Francisca Matus, and Tomas Poblete, and Jessica Amigo, and Gabriel Vallejos, and Luis Astudillo
February 2009, European journal of medicinal chemistry,
Margarita Gutiérrez, and María Francisca Matus, and Tomas Poblete, and Jessica Amigo, and Gabriel Vallejos, and Luis Astudillo
November 2014, Bioorganic & medicinal chemistry,
Margarita Gutiérrez, and María Francisca Matus, and Tomas Poblete, and Jessica Amigo, and Gabriel Vallejos, and Luis Astudillo
March 2009, European journal of medicinal chemistry,
Margarita Gutiérrez, and María Francisca Matus, and Tomas Poblete, and Jessica Amigo, and Gabriel Vallejos, and Luis Astudillo
January 2015, Yao xue xue bao = Acta pharmaceutica Sinica,
Margarita Gutiérrez, and María Francisca Matus, and Tomas Poblete, and Jessica Amigo, and Gabriel Vallejos, and Luis Astudillo
October 2013, Journal of enzyme inhibition and medicinal chemistry,
Margarita Gutiérrez, and María Francisca Matus, and Tomas Poblete, and Jessica Amigo, and Gabriel Vallejos, and Luis Astudillo
March 2014, Yao xue xue bao = Acta pharmaceutica Sinica,
Margarita Gutiérrez, and María Francisca Matus, and Tomas Poblete, and Jessica Amigo, and Gabriel Vallejos, and Luis Astudillo
July 2008, Bioorganic & medicinal chemistry letters,
Margarita Gutiérrez, and María Francisca Matus, and Tomas Poblete, and Jessica Amigo, and Gabriel Vallejos, and Luis Astudillo
September 2016, Yao xue xue bao = Acta pharmaceutica Sinica,
Margarita Gutiérrez, and María Francisca Matus, and Tomas Poblete, and Jessica Amigo, and Gabriel Vallejos, and Luis Astudillo
June 2015, Yao xue xue bao = Acta pharmaceutica Sinica,
Margarita Gutiérrez, and María Francisca Matus, and Tomas Poblete, and Jessica Amigo, and Gabriel Vallejos, and Luis Astudillo
March 2022, Molecules (Basel, Switzerland),
Copied contents to your clipboard!